CN115531592A - 一种实现皮肤高效修复的皮肤敷料及其制备方法 - Google Patents
一种实现皮肤高效修复的皮肤敷料及其制备方法 Download PDFInfo
- Publication number
- CN115531592A CN115531592A CN202211340071.7A CN202211340071A CN115531592A CN 115531592 A CN115531592 A CN 115531592A CN 202211340071 A CN202211340071 A CN 202211340071A CN 115531592 A CN115531592 A CN 115531592A
- Authority
- CN
- China
- Prior art keywords
- skin
- dressing
- woven
- skin dressing
- plga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 32
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 229930003231 vitamin Natural products 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 102000009123 Fibrin Human genes 0.000 claims abstract description 19
- 108010073385 Fibrin Proteins 0.000 claims abstract description 19
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229950003499 fibrin Drugs 0.000 claims abstract description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 18
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 11
- 102000004506 Blood Proteins Human genes 0.000 claims abstract description 9
- 108010017384 Blood Proteins Proteins 0.000 claims abstract description 9
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 9
- 229940087168 alpha tocopherol Drugs 0.000 claims abstract description 9
- 229960002477 riboflavin Drugs 0.000 claims abstract description 9
- 229960000984 tocofersolan Drugs 0.000 claims abstract description 9
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 9
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 9
- 239000002076 α-tocopherol Substances 0.000 claims abstract description 9
- 235000004835 α-tocopherol Nutrition 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 238000007605 air drying Methods 0.000 claims abstract description 6
- 238000004140 cleaning Methods 0.000 claims abstract description 6
- 239000002131 composite material Substances 0.000 claims abstract description 6
- 238000002791 soaking Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 10
- 239000004626 polylactic acid Substances 0.000 claims description 10
- 238000009987 spinning Methods 0.000 claims description 10
- 238000010041 electrostatic spinning Methods 0.000 claims description 7
- 239000011148 porous material Substances 0.000 claims description 6
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 5
- DEVXQDKRGJCZMV-UHFFFAOYSA-K Aluminum acetoacetate Chemical compound [Al+3].CC(=O)CC([O-])=O.CC(=O)CC([O-])=O.CC(=O)CC([O-])=O DEVXQDKRGJCZMV-UHFFFAOYSA-K 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 239000011261 inert gas Substances 0.000 claims description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 5
- 238000000464 low-speed centrifugation Methods 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 210000003462 vein Anatomy 0.000 claims description 5
- CHJMFFKHPHCQIJ-UHFFFAOYSA-L zinc;octanoate Chemical compound [Zn+2].CCCCCCCC([O-])=O.CCCCCCCC([O-])=O CHJMFFKHPHCQIJ-UHFFFAOYSA-L 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000010261 cell growth Effects 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 230000019522 cellular metabolic process Effects 0.000 abstract description 2
- 239000002861 polymer material Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 43
- 206010052428 Wound Diseases 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 238000000635 electron micrograph Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229920001002 functional polymer Polymers 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 108010088880 plasmagel Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明属于皮肤敷料的技术领域，具体涉及一种实现皮肤高效修复的皮肤敷料及其制备方法。所述皮肤敷料的组分包括维生素、血浆纤维蛋白以及无纺布PLGA材料；所述维生素包括维生素B2以及α‑生育酚；其制备为将无纺布PLGA材料用NaOH处理，之后用纯水清洗，再用75%乙醇浸泡，在无菌操作台里风干过夜；取人体血浆蛋白混合维生素，均匀滴加在无纺布PLGA材料上，再以75~80℃加热所得复合材料，即得到皮肤敷料。本发明所采用的皮肤敷料可以进行细胞新陈代谢，并且这种具有生物凝胶的高分子材料，具有一定的结构，利于细胞长入，促进植皮皮肤的成活效率。
Description
技术领域
本发明属于皮肤敷料的技术领域，具体涉及一种实现皮肤高效修复的皮肤敷料及其制备方法。
背景技术
皮肤是人体第一道屏障，皮肤出现问题，带给病人身体压力的同时，也给社会和个人带来巨大经济压力。皮肤一旦出现损伤，促进皮肤尽快修复刻不容缓。临床上皮肤敷料主要分为：1.被动型敷料（传统敷料），指的是被动覆盖创面和吸收渗出物，为创面提供有限的保护作用，如纱布；2.相互作用型敷料，指的是敷料与创面之间存在着多种形式的相互作用，如吸收渗出液以及有毒物质、允许气体交换，从而为愈合创造一个理想的环境；阻隔性外层结构，防止环境中微生物侵入，预防创面交叉感染等，如负压吸引敷料装置；3.生物活性敷料（密闭性敷料）这类敷料因可防止创面干燥又称为密闭性敷料，如生长因子凝胶敷料，抗菌凝胶敷料。皮肤修复的过程中，除了需要保证创面不受外界污染以外，还需要多种营养物质的参与。由于皮肤损伤，机体会启动一系列的反应，如增加生长因子的释放从而启动自我修复，但是维生素的缺乏需要从外界补充，如何同时实现局部实现维生素的补充对未来皮肤敷料提出了一定的挑战。
发明内容
针对上述问题，本发明的目的在于提供一种实现皮肤高效修复的皮肤敷料及其制备方法。
本发明的技术内容如下：
本发明提供了一种实现皮肤高效修复的皮肤敷料，所述皮肤敷料的组分包括维生素、血浆纤维蛋白以及无纺布PLGA材料；
所述维生素包括维生素B2以及α-生育酚；
所述维生素B2的使用浓度为10~20 mg/mL；
所述α-生育酚的使用浓度为50~100 mg/mL；
所述血浆纤维蛋白占无纺布PLGA材料的20~40 wt%；
所述无纺布PLGA材料的孔隙大小为100~200 nm，纤维直径为15~20 μm，厚度为0.1~0.5 cm；
其制备方法为：取丙交酯和乙交酯，加入乙酰乙酸铝和辛酸锌，在惰性气体氛围下，进行180~220℃的高温反应，反应3~8h，反应压力为30~40 MPa，得到聚乳酸，将冷却之后的聚乳酸溶于有机溶剂中，得到纺丝液，进行静电纺丝，即得到无纺布PLGA材料；
所述静电纺丝的条件为：纺丝液的流速为 1~3 mL/h，电压为18~20 kV。
所述血浆纤维蛋白的提取方法为：静脉采取抗凝血液，采用低速离心（600g*15min）之后，吸出上层含有纤维蛋白的血浆层，即为血浆纤维蛋白。
本发明还提供了一种实现皮肤高效修复的皮肤敷料的制备方法，包括如下步骤：
1）将无纺布PLGA材料用NaOH处理，之后用纯水清洗，再用75%乙醇浸泡，在无菌操作台里风干过夜；
2）取人体血浆蛋白混合维生素，均匀滴加在步骤1）处理过后的无纺布PLGA材料上，再以75~80℃加热所得复合材料，即得到皮肤敷料。
本发明的有益效果如下：
本发明所述实现皮肤高效修复的皮肤敷料，所采用的维生素B2参与体内生物氧化与能量代谢，与碳水化合物、蛋白质、核酸和脂肪的代谢有关，可提高人体对蛋白质的吸收和利用，可以维护皮肤和细胞膜的完整性，具有保护皮肤毛囊粘膜及皮脂腺的功能，还具有一定的抗氧化功能；α-生育酚是维生素E的一种，它是一种很强的抗氧化剂，激发机体的免疫系统，杀死新产生的变形细胞，具有维持结缔组织弹性，促进血液循环，延缓衰老，调节体内激素正常分泌，控制体内酸素消耗，保护皮肤粘膜等功能；PLGA指的是聚乳酸-羟基乙酸共聚物，由两种单体—乳酸和羟基乙酸随机聚合而成，是一种可降解的功能高分子有机化合物，具有良好的生物相容性、无毒；人体血浆含有丰富的纤维蛋白，通过离心和加热除去对人体具有免疫原性的物质，同时加热可将促进纤维蛋白的凝聚从而将血浆形成血浆凝胶。
本发明所采用的皮肤敷料可以进行细胞新陈代谢，并且这种具有生物凝胶的高分子材料，具有一定的结构，利于细胞长入，促进植皮皮肤的成活效率，因此这种手术方式可减少病人痛苦症状，增加皮片存活率，促进创面修复速度，增加社会经济效益。
附图说明
图1为血浆纤维蛋白的凝胶电镜图；
图2为无纺布PLGA材料的凝胶电镜图；
图3为本发明的皮肤敷料的凝胶电镜图；
图4为本发明的皮肤敷料的维生素释放曲线图；
图5为本发明的皮肤敷料用于动物皮肤损伤创面修复效果图。
具体实施方式
以下通过具体的实施案例以及附图说明对本发明作进一步详细的描述，应理解这些实施例仅用于说明本发明而不用于限制本发明的保护范围，在阅读了本发明之后，本领域技术人员对本发明的各种等价形式的修改均落于本申请所附权利要求所限定。
若无特殊说明，本发明的所有原料和试剂均为常规市场的原料、试剂。
实施例1
一种实现皮肤高效修复的皮肤敷料的制备方法：
1）将无纺布PLGA材料用0.1M的NaOH处理2min，之后用纯水清洗3次，每次10 min，再用75%乙醇浸泡2h，在无菌操作台里风干过夜；
所述无纺布PLGA材料的制备方法为：取丙交酯和乙交酯质量比为1:1，加入0.2wt%乙酰乙酸铝和0.2wt%辛酸锌，在惰性气体氛围下，进行200℃的高温反应，反应5h，反应压力为35 MPa，得到聚乳酸，将冷却之后的聚乳酸溶于有机溶剂中，得到纺丝液，进行静电纺丝，纺丝液的流速为 2 mL/h，电压为18 kV，即得到无纺布PLGA材料，所得无纺布PLGA材料的孔隙大小为100~200 nm，纤维直径为15~20 μm，厚度为0.1~0.5 cm；
2）取55 μL人体血浆蛋白混合维生素，均匀滴加在步骤1）处理过后的无纺布PLGA材料上，再以78℃加热所得复合材料7 min，即得到皮肤敷料；
所述人体血浆蛋白为通过静脉采抗凝血液20mL，采用低速离心600g*15min之后，吸出上层含有纤维蛋白的血浆层得到；
所述维生素中，维生素B2的使用浓度为15 mg/mL，α-生育酚的使用浓度为80 mg/mL。
如图1所示，为所采用的血浆纤维蛋白的凝胶电镜图，可见纤维蛋白凝胶充斥整个视野形成含有多孔的结构，这种多孔结构方便负载细胞活性物质并实现这些活性物质的持续性释放；
如图2所示，为所采用的无纺布PLGA材料的凝胶电镜图，可见PLGA丝状，直径在20um左右，PLGA丝互相缠绕形成含有几十到几百的微孔结构，方便细胞长入；
如图3所示，为本发明的皮肤敷料的凝胶电镜图，可见纤维蛋白凝胶均匀地分布在PLGA丝之间，填补PLGA丝之间的孔隙，形成松散的纤维丝结构；
如图4所示，为本发明的皮肤敷料的维生素释放曲线图，可见维生素可实现3周以上的持续性释放，3周后释放的含量逐渐下降。
实施例2
一种实现皮肤高效修复的皮肤敷料的制备方法：
1）将无纺布PLGA材料用0.1M的NaOH处理2min，之后用纯水清洗3次，每次10 min，再用75%乙醇浸泡2h，在无菌操作台里风干过夜；
所述无纺布PLGA材料的制备方法为：取丙交酯和乙交酯质量比为2:1，加入0.2wt%乙酰乙酸铝和0.2wt%辛酸锌，在惰性气体氛围下，进行220℃的高温反应，反应3h，反应压力为40 MPa，得到聚乳酸，将冷却之后的聚乳酸溶于有机溶剂中，得到纺丝液，进行静电纺丝，纺丝液的流速为 3 mL/h，电压为20 kV，即得到无纺布PLGA材料，所得无纺布PLGA材料的孔隙大小为100~200 nm，纤维直径为15~20 μm，厚度为0.1~0.5 cm；
2）取55 μL人体血浆蛋白混合维生素，均匀滴加在步骤1）处理过后的无纺布PLGA材料上，再以78℃加热所得复合材料7 min，即得到皮肤敷料；
所述人体血浆蛋白为通过静脉采抗凝血液20mL，采用低速离心600g*15min之后，吸出上层含有纤维蛋白的血浆层得到；
所述维生素中，维生素B2的使用浓度为20 mg/mL，α-生育酚的使用浓度为100 mg/mL。
实施例3
一种实现皮肤高效修复的皮肤敷料的制备方法：
1）将无纺布PLGA材料用0.1M的NaOH处理2min，之后用纯水清洗3次，每次10 min，再用75%乙醇浸泡2h，在无菌操作台里风干过夜；
所述无纺布PLGA材料的制备方法为：取丙交酯和乙交酯质量比为1:2，加入0.2wt%乙酰乙酸铝和0.2wt%辛酸锌，在惰性气体氛围下，进行180℃的高温反应，反应8h，反应压力为30 MPa，得到聚乳酸，将冷却之后的聚乳酸溶于有机溶剂中，得到纺丝液，进行静电纺丝，纺丝液的流速为1 mL/h，电压为18 kV，即得到无纺布PLGA材料，所得无纺布PLGA材料的孔隙大小为100~200 nm，纤维直径为15~20 μm，厚度为0.1~0.5 cm；
2）取55 μL人体血浆蛋白混合维生素，均匀滴加在步骤1）处理过后的无纺布PLGA材料上，再以78℃加热所得复合材料7 min，即得到皮肤敷料；
所述人体血浆蛋白为通过静脉采抗凝血液20mL，采用低速离心600g*15min之后，吸出上层含有纤维蛋白的血浆层得到；
所述维生素中，维生素B2的使用浓度为10 mg/mL，α-生育酚的使用浓度为50 mg/mL。
如图5所示，为将本发明所得皮肤敷料敷用于有创口的动物皮肤身上，可见经修复的创口越来越小，修复具有显著效果。
Claims (7)
1.一种实现皮肤高效修复的皮肤敷料，其特征在于，所述皮肤敷料的组分包括维生素、血浆纤维蛋白以及无纺布PLGA材料；
所述维生素包括维生素B2以及α-生育酚。
2.根据权利要求1所述的实现皮肤高效修复的皮肤敷料，其特征在于，所述皮肤敷料中，所述维生素B2的使用浓度为10~20 mg/mL；
所述α-生育酚的使用浓度为50~100 mg/mL。
3.根据权利要求1所述的实现皮肤高效修复的皮肤敷料，其特征在于，所述无纺布PLGA材料的孔隙大小为100~200 nm，纤维直径为15~20 μm，厚度为0.1~0.5 cm。
4.根据权利要求3所述的实现皮肤高效修复的皮肤敷料，其特征在于，所述无纺布PLGA材料的制备方法为：取丙交酯和乙交酯，加入乙酰乙酸铝和辛酸锌，在惰性气体氛围下，进行180~220℃的高温反应，反应3~8h，反应压力为30~40 MPa，得到聚乳酸，将冷却之后的聚乳酸溶于有机溶剂中，得到纺丝液，进行静电纺丝，即得到无纺布PLGA材料。
5.根据权利要求4所述的实现皮肤高效修复的皮肤敷料，其特征在于，所述静电纺丝的条件为：纺丝液的流速为 1~3 mL/h，电压为18~20 kV。
6.根据权利要求1所述的实现皮肤高效修复的皮肤敷料，其特征在于，所述血浆纤维蛋白的提取方法为：静脉采取抗凝血液，采用低速离心之后，吸出上层含有纤维蛋白的血浆层，即为血浆纤维蛋白。
7.一种权利要求1~6任一项所述的实现皮肤高效修复的皮肤敷料的制备方法，其特征在于，包括如下步骤：
1）将无纺布PLGA材料用NaOH处理，之后用纯水清洗，再用75%乙醇浸泡，在无菌操作台里风干过夜；
2）取人体血浆蛋白混合维生素，均匀滴加在步骤1）处理过后的无纺布PLGA材料上，再以75~80℃加热所得复合材料，即得到皮肤敷料。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211340071.7A CN115531592A (zh) | 2022-10-27 | 2022-10-27 | 一种实现皮肤高效修复的皮肤敷料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211340071.7A CN115531592A (zh) | 2022-10-27 | 2022-10-27 | 一种实现皮肤高效修复的皮肤敷料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115531592A true CN115531592A (zh) | 2022-12-30 |
Family
ID=84719238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211340071.7A Pending CN115531592A (zh) | 2022-10-27 | 2022-10-27 | 一种实现皮肤高效修复的皮肤敷料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115531592A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160653A1 (en) * | 2006-01-11 | 2007-07-12 | Fischer Thomas H | Hemostatic textile |
| US20080095830A1 (en) * | 2006-10-20 | 2008-04-24 | Van Holten Robert W | Method for making a dressing |
| US20090181072A1 (en) * | 2006-05-18 | 2009-07-16 | Lnk Chemsolutions, Llc | Methods for Making a Multicomponent Hemostatic Dressing |
| CN108096624A (zh) * | 2018-01-22 | 2018-06-01 | 叶川 | 细胞支架材料的制备方法、材料及应用 |
| US20210252182A1 (en) * | 2018-08-27 | 2021-08-19 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
-
2022
- 2022-10-27 CN CN202211340071.7A patent/CN115531592A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160653A1 (en) * | 2006-01-11 | 2007-07-12 | Fischer Thomas H | Hemostatic textile |
| US20090181072A1 (en) * | 2006-05-18 | 2009-07-16 | Lnk Chemsolutions, Llc | Methods for Making a Multicomponent Hemostatic Dressing |
| US20080095830A1 (en) * | 2006-10-20 | 2008-04-24 | Van Holten Robert W | Method for making a dressing |
| CN108096624A (zh) * | 2018-01-22 | 2018-06-01 | 叶川 | 细胞支架材料的制备方法、材料及应用 |
| US20210252182A1 (en) * | 2018-08-27 | 2021-08-19 | Advamedica Inc. | Composite dressings, manufacturing methods and applications thereof |
Non-Patent Citations (1)
| Title |
|---|
| 刘淑强主编: "化学纤维设备", 东华大学出版社, pages: 195 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI445555B (zh) | 含積雪草活性成分之敷材及其應用 | |
| US11622979B2 (en) | Bone derived fibers and oxygenated wound treatments | |
| Límová | Active wound coverings: bioengineered skin and dermal substitutes | |
| Zhou et al. | Rational design of intelligent and multifunctional dressing to promote acute/chronic wound healing | |
| WO2016004212A1 (en) | Hydrogels for treating and ameliorating wounds and methods for making and using them | |
| CN109106977B (zh) | 一种用于糖尿病创面修复的自愈合可注射水凝胶敷料及其制备方法与应用 | |
| CN103071191A (zh) | 一种自体富血小板因子血浆pfrp制剂的制备方法 | |
| CN107496972B (zh) | 一种促烧伤创面愈合的防粘连湿性敷料及其制备方法 | |
| CN103480042B (zh) | 一种人工硬脊膜及其制备方法和使用方法 | |
| CN108283727A (zh) | 一种纳米纤维敷料及其制备方法 | |
| CN112999297A (zh) | 用于瘢痕治疗的微针贴片及其制备方法 | |
| CN111690600A (zh) | 一种工程化人脐带间充质干细胞外泌体及透皮制剂与应用 | |
| CN114618026A (zh) | 一种可促进骨再生的屏障膜及其制备方法 | |
| CN115531592A (zh) | 一种实现皮肤高效修复的皮肤敷料及其制备方法 | |
| CN110841104B (zh) | 一种红景天苷-胶原蛋白海绵支架的制备方法及在皮肤创伤修复的应用 | |
| CN110420344B (zh) | 一种伤口敷料及其制备方法与应用 | |
| WO2015200819A1 (en) | Angiogenic devices for wound care | |
| CN112807485A (zh) | 一种无干细胞和生长因子负载的可注射聚（4-羟基丁酸酯）（p4hb）多孔微球制剂 | |
| CN219021921U (zh) | 一种敷料 | |
| CN114949358A (zh) | 一种用于深部创面修复的复合材料及其制备方法 | |
| CN112999411B (zh) | 具备压力可铺展性的丝蛋白纳米纤维凝胶敷料、其制备方法及应用 | |
| Ilomuanya et al. | Polymeric biomaterials for wound healing incorporating plant extracts and extracellular matrix components | |
| CN116036355B (zh) | 一种人脂肪脱细胞外基质膜及其制备方法与应用 | |
| CN111821520B (zh) | 一种负载活性生物玻璃的皮肤再生材料及其制备方法 | |
| CN116850333B (zh) | 一种复合纳米纤维敷料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |